摘要
目的 为了给临床选择乳腺癌术后辅助治疗方案提供参考依据,探讨乳腺癌预后因素的判断指标。方法 对198例乳腺癌组织蜡块,采用SABC法标记PCNA、C-erbB-2,亲和组化法标记ER、PR,分析其与年龄、病理类型、发病时月经状况、肿瘤大小及淋巴结转移数诸因素的相关性。结果 PCNA的表达与病理类型、淋巴结转移数及发病时月经状况有显著相关(P<0.05);C-erbB-2的表达亦与淋巴结转移及月经状况有显著相关(P<0.05)。ER、PR的表达均与月经状况显著相关(ER:P=0.000,PR:P=0.004)。C-erbB-2高表达与ER呈负相关(r=0.2337,P=0.001)。结论 PCNA高表达预后不良的标记,C-erbB-2高表达可为辅助治疗方案的选择提供依据。
Objective In order to provide the objective evidences for the patient after breast cancer surgery in planning the therapeutic program and predicting the prognosis. Methods The expression of PCNA and C-erbB-2 were detected by SABC method. ER and PR were examined by affinity- histochemistry method with paraffin-embedded sections for 198 cases. The correlation analysis among the markers and the ages, pathological types, status of menstruation, sizes of tumor and lymph-node metastasis were done. Results The results showed that the expression of PCNA was significantly correlated with the pathological type of cancer, and the lymph-node metastasis and the status of menstruation (P<0. 05). The expression of C-erbB-2 was significantly correlated with the lymph-node metastasis and the status of menstruation (P<0. 05) as well. The expressions of ER and PR were significantly correlated with the status of menstruation. (ER: P = 0. 000, PR:F = 0. 004); The over-expression of C-erbB-2 was negatively correlated with the expression of ER (r = -0. 2337, P = 0. 001). Conclusions The over-expression of PCNA is a marker showing the poor prognosis, and the over-experssion of C-erbB-2 can be the evidence for programming the sequential therapy.
